Cystic Hygroma was first discussed in the year 1843 by Wernher, where it was said to be a congenital defect causing lesions in any anatomic site in the body. Abbreviated as (CH), it is caused due to genetic defects in the lymphatic system near the head and neck region. Inside the neck, the posterior part is the most frequent area that is likely to be affected with cyst formation. As the baby in the womb develops, Cystic Hygroma can also develop simultaneously. The lump or mass may be filled with fluid which includes white blood cells and pieces of tissue forming the lymphatic system. If this defect is not diagnosed during gestation then the newborn may show a lump on its neck or head region after the delivery.
Due to medical advancements and hi tech Ultrasound machines it is now possible to locate CH in an unborn child during sonography. CT scan may also be required for the same. Doctors recommend removal of the cyst through surgical procedures but it poses threat for post-surgery complications such as bleeding or regrowth of the CH. These days drug therapy in which sclerosing agent such as OK-432 is under experimental studies indicating some promising results which can be used to treat Cystic Hygroma. Currently OK-432(Picibanil) is not approved by USFDA but protocol suggest a successful prognosis with the administration of this potential sclerosant.